ATE473211T1 - Renininhibitoren - Google Patents

Renininhibitoren

Info

Publication number
ATE473211T1
ATE473211T1 AT07845514T AT07845514T ATE473211T1 AT E473211 T1 ATE473211 T1 AT E473211T1 AT 07845514 T AT07845514 T AT 07845514T AT 07845514 T AT07845514 T AT 07845514T AT E473211 T1 ATE473211 T1 AT E473211T1
Authority
AT
Austria
Prior art keywords
renin inhibitors
formula
relates
present
inhibitor compounds
Prior art date
Application number
AT07845514T
Other languages
English (en)
Inventor
Daniel Dube
Michel Gallant
Erich L Grimm
Helene Juteau
Sebastien Laliberte
Tom Yao-Hsiang Wu
Original Assignee
Merck Frosst Canada Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd filed Critical Merck Frosst Canada Ltd
Application granted granted Critical
Publication of ATE473211T1 publication Critical patent/ATE473211T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
AT07845514T 2006-11-17 2007-11-14 Renininhibitoren ATE473211T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85991406P 2006-11-17 2006-11-17
PCT/CA2007/002044 WO2008058387A1 (en) 2006-11-17 2007-11-14 Renin inhibitors

Publications (1)

Publication Number Publication Date
ATE473211T1 true ATE473211T1 (de) 2010-07-15

Family

ID=39401281

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07845514T ATE473211T1 (de) 2006-11-17 2007-11-14 Renininhibitoren

Country Status (8)

Country Link
US (1) US8076359B2 (de)
EP (1) EP2097377B1 (de)
JP (1) JP2010510176A (de)
AT (1) ATE473211T1 (de)
AU (1) AU2007321671A1 (de)
CA (1) CA2668742A1 (de)
DE (1) DE602007007664D1 (de)
WO (1) WO2008058387A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8129538B1 (en) 2007-03-28 2012-03-06 Takeda Pharmaceutical Company Limited Renin inhibitors
JP2010527942A (ja) * 2007-05-24 2010-08-19 メルク フロスト カナダ リミテツド 新規類のレニン阻害剤
WO2009023964A1 (en) 2007-08-20 2009-02-26 Merck Frosst Canada Ltd. Renin inhibitors
WO2009135299A1 (en) * 2008-05-05 2009-11-12 Merck Frosst Canada Ltd. 3, 4 - substituted piperidine derivatives as renin inhibitors
US20120115907A1 (en) * 2009-04-24 2012-05-10 Cadila Healthcare Limited Novel compounds as inhibitors of renin
WO2012085935A2 (en) * 2010-12-22 2012-06-28 Cadila Healthcare Limited Compounds as inhibitors of renin
WO2013084241A1 (en) 2011-12-09 2013-06-13 Cadila Healthcare Limited Compounds as inhibitors of renin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06500111A (ja) * 1990-08-15 1994-01-06 アボツト・ラボラトリーズ レニン阻害剤
NZ315677A (en) * 1995-09-07 2000-02-28 F 4-(oxyalkoxyphenyl)-3-oxy-piperidines for treating heart and kidney insufficiency
US20040204455A1 (en) 2003-04-10 2004-10-14 Cody Wayne Livingston Piperidine derivative rennin inhibitors
GB0504850D0 (en) * 2005-03-09 2005-04-13 Novartis Ag Organic compounds
JP2010527942A (ja) 2007-05-24 2010-08-19 メルク フロスト カナダ リミテツド 新規類のレニン阻害剤

Also Published As

Publication number Publication date
EP2097377A4 (de) 2009-12-02
DE602007007664D1 (de) 2010-08-19
EP2097377A1 (de) 2009-09-09
AU2007321671A1 (en) 2008-05-22
US20100063091A1 (en) 2010-03-11
CA2668742A1 (en) 2008-05-22
US8076359B2 (en) 2011-12-13
JP2010510176A (ja) 2010-04-02
WO2008058387A1 (en) 2008-05-22
EP2097377B1 (de) 2010-07-07

Similar Documents

Publication Publication Date Title
EA200870029A1 (ru) Способ применения антагонистов il-6 с ингибиторами протеасом
ECSP10010568A (es) Inhibidores de la renina
ATE473211T1 (de) Renininhibitoren
NO20081636L (no) FAP - inhibitorer
MX2009003834A (es) Derivados de pirrolidina como inhibidores de iap.
ATE543816T1 (de) Azacycloalkanderivate als inhibitoren von stearoyl-coenzym-a-delta-9-desaturase
GEP20125652B (en) cMET INHIBITORS
SMAP200900031A (it) Composti e composizioni come inibitori di proteinachinasi
ECSP066893A (es) Inhibidores de proteínas de apoptosis (iap)
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
MY152042A (en) 3,4- substituted piperidine derivatives as renin inhibitors
SMP200900058B (it) Composti e composizioni come inibitori di proteinachinasi.
SM201000108A (it) Composti e composizioni come inibitori di proteinachinasi.
ATE471324T1 (de) Triazolophthalazine
MX2009005934A (es) Compuestos organicos.
MX2007008137A (es) Triazoloftalazinas como inhibidores de pde2.
NO20083492L (no) 11-Beta HSD1 inhibitorer
DE112006002052A5 (de) Nicht-Peptidische Inhibitoren der AKAP-PKA-Wechselwirkung
EA201100880A1 (ru) Бензонафтиридиновые соединения в качестве ингибиторов аутотаксина
EA201170052A1 (ru) Производные тиофена или тиазола и их применение как ингибиторов pi3k
TW200833687A (en) Substituted piperidines
NO20090010L (no) Nye indikasjoner for direkte trombininhibitorer innenfor det kardiovaskulaere feltet
MX2010008397A (es) Inhibidores del receptor de quimioquinas cxcr3.
WO2008009639A3 (en) New indications for direct thrombin inhibitors
EA201000257A1 (ru) Новый способ синтеза (7-метокси-l-нафтил) ацетонитрила и применение в синтезе агомелатина

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties